selected publications
- Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis. bioRxiv : the preprint server for biology. 2026 Article GET IT
-
A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin.
Nucleic acids research.
2025
Academic Article
GET IT
Times cited: 4 -
Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis.
Cancers.
2024
Academic Article
GET IT
Times cited: 3 - A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN. bioRxiv : the preprint server for biology. 2024 Article GET IT
-
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Cancer letters.
2024
Academic Article
GET IT
Times cited: 12 -
p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome.
Nature communications.
2024
Academic Article
GET IT
Times cited: 20 - Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. bioRxiv : the preprint server for biology. 2023 Article GET IT
-
The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Molecular cancer research : MCR.
2022
Academic Article
GET IT
Times cited: 3 -
Mutant C. elegans p53 Together with Gain-of-Function GLP-1/Notch Decreases UVC-Damage-Induced Germline Cell Death but Increases PARP Inhibitor-Induced Germline Cell Death.
Cancers.
2022
Academic Article
GET IT
Times cited: 2 -
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Frontiers in oncology.
2022
Academic Article
GET IT
Times cited: 12 -
Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Frontiers in cell and developmental biology.
2021
Academic Article
GET IT
Times cited: 8 -
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Cancer research.
2019
Academic Article
GET IT
Times cited: 65 -
Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis.
Oncotarget.
2019
Academic Article
GET IT
Times cited: 4 -
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Breast cancer research : BCR.
2019
Academic Article
GET IT
Times cited: 38 -
Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Oncotarget.
2017
Academic Article
GET IT
Times cited: 25 -
Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
International journal of environmental research and public health.
2015
Academic Article
GET IT
Times cited: 19 -
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Proceedings of the National Academy of Sciences of the United States of America.
2015
Academic Article
GET IT
Times cited: 82 -
Multiple roles of the tumor suppressor p53.
Current opinion in oncology.
2002
Information Resource
GET IT
Times cited: 325